




Generation Change in Biopharmaceuticals Production From Fed-Batch to Hybrid Processes

Key Facts About the Global Pharmaceutical Industry in 2013





330 Mrd. € gross value addd in 2013 – equivalent to the gross domestic product of Austria in


4.8 million employees – equivalent to the polulation of Ireland.

3.9 % annual growth rate of employment from 2005 bis

Data taken from The World Bank Group, 2015 ; WifOR calculation; WifOR illustration


Approvals for Biopharmaceuticals on the EU Are Higher than Ever






Biotech-Report 2017

Germany's Biopharmaceutical Pipeline Is Well-Filled **Rentschler** 2/3 of active ingredients are monoclonal antibodies



Pharmaceutical Location Germany The biggest in Europe (EU28 + Switzerland, 2015)






EFPIA, IW Köln

Number 2 in Europe, Number 4 in the World




Clinical Studies



6

A Seemingly Easy Way from Gene to Therapy







Factors affecting protein stability

Pioneering Cell Culture Bioprocesses in 1967





Paul van Hemert with the so-called "Bilthoven Unit" with a Polio virus vaccine production bioreactor in 1967.



Filled with cells grown on microcarriers (Anton van Wezel. 1967. Nature 216: 64).

From Basic Pilot Research to Manufacturing Sciences Rentschler




1990: GBF's 100 | Pilot Plant for cell culture-based bioprocess research



2015: Rentschler's 2x 3000 I TWIN Facility for cell culture-based biopharmaceutical manufacturing

Celldays Increased Within 20 Years By a Factor of 10 Rentschler Titer Increased Within 20 Years by a Factor of 20




High-End Cell Culture Processes Are Approaching Natural Blood Cell Concentrations



Cell concentration in bioreactor: $1.25 \times 10^8 \text{ ml}^{-1}$ 25 % packed cell volume $\emptyset = 10-20 \ \mu\text{m}$


Cell concentration in blood: 5-10 × 10⁹ ml⁻¹ 50 % packed cell volume $\emptyset = 7.5 \ \mu m$



Boost Performed by Cell Culture Technologists



A fantastic job over the last 20 years



Drivers are

- **Improving Safety** to patients (CD media) Ο
- Improved Control & Consistency Ο
- Development Time Line Acceleration Ο
- In principle for antibodies and Fc-fusion proteins

Improved Cell Culture Production is Driven by



• Safety, Control and Robustness


- o Enhanced patient safety
- Improved process robustness and consistency
- Tailor-made product **quality** (comparability & similarity)

• Efficiency, Potency and Cost

- Enhanced **productivity** and facility output (titer and volumetric productivity)
- Excellent pharmacokinetics
- Reduced processing time
- Reduced process scale
- Ease downstream operation
- Ease technology transfer
- Overall **cost** reduction (cost per gram of product produced)

Only 3 % of the Genes Are Different in Humans and Rodents








Chinese hamster *Cricetulus griseus* Industrial cell line provider

Graphodatsky AS et al. 2011. Mol Cytogen 4: 22


The CHOdyssee





Wurm F. 2015. In Hauser H, Wagner R. Animal Cell Biotechnology in Biologics Production. WdG, Berlin

The CHrOmosomes The world of quasispecies





Cricetulus griseus Starts in 1919 for typing pneumcococci




† 1957 Lifespan: 2-4 years

2n = 22 Chromosomen predestinate it for research of radiation cytogenetics

Typical Antibody Manufacturing Process Over the Last 20 Years





Cell Banks and Seeding Intensification




- Increasing starting cell mass and reducing initial expansion steps
 - Rolling seed train
 - High cell concentration in vials or bags
 - Frozen seed train intermediates in bags

Basic Strategy	Advantage	Disadvantage
One Vial Only Batch	 Batch to batch identical seed train Identical population doublings Identical cell age 	 More WCB vials used More labor intensive RELIABLE
Rolling Seed Train (small scale bioreactors)	 Less labor intensive Less WCB vials used Reduced number of seed train stages for each production run FAST	 Each batch has a different seed train history Each batch has different cell age Cell line stability limits FAILURE-PRONE

Heidemann R et al. 2002. Cytotechnology 38: 99-108; Heidemann R et al. 2010. Biotechnol Prog 26: 1154-1163; Tao YW et al. 2011. Biotechnol Prog 27: 824-829; Seth G et al. 2013. Biotechnol Biotechnol Bioeng 110: 1376-1385; Clincke MF et al. 2013. Biotechnol Prog 29: 768 - 777

Cell Banks and Seed Intensification

High cell number working cell bank






Cell line

Cell line 2 Cell line 3

---- Cell line 4



Production Culture Intensification

From batch to hybrid processes




Pre 1990		Legacy Processes	Current Best Practice	Future State	
Batch Culture	Simple Fed-Batch	Complex Fed- Batch	High Efficiency Fed-Batch	Controlled Fed-Batch	Hybrid Process
No feeding Belov	Glucose, Glutamine	Complex feed, includes hydrolysates, 1 – 3 bolus feeds 1 - 3 g l⁻¹ ("2 g l ⁻¹ in 2 weeks")	CD feed, daily or continuous feeding, potentially multiple feed streams 5 - 10 g l⁻¹	Multiple CD feed streams, continuous or discrete addition controlled through feedback loops and advanced monitoring	Continuously perfused process for 4 days followed by a controlled fed- batch

> 10 g l⁻¹

Effects of Accelerated Feed Strategy






Fed-Batch Production Improvements Over the Last 20 Years Iso-Titer Lines in Efficiency / Intensity Space



- Media / Feed Optimization
 - o CD formulas, balanced feeding
- Host Cell Line that grows to high cell mass
 - o Adapted to process materials and format
- Improved Process Control
 - Feedback loop driven feeding: Feed per cell, Glc / Lac control
 - Lactogenesis: HIPDOG, HIPCOP




Cellsp. Productivity [pg d ⁻¹]	Integral Cell Mass [10 ⁶ ml ⁻¹]	Titer [g l ⁻¹]	Year
20	20	1	1990
30	70	2.5	- 2005
50	100	5	- 2010
50	200	10	> 2015
50	300	15	> 2017

Perfusion Applications:

- Perfusion supported Fed-Batch
- Concentrated Fed-Batch
- High Density Perfusion Culture

Combining Benefits of Fed-Batch and Perfusion to Hybrid Processes





N-1 Perfusion Seed culture Perfusion followed by Fed-Batch


Hybrid Perfusion - Fed-Batch

Perfusion during Fed-Batch growth phase to boost cell mass

Concentrated Fed-Batch

Perfusion during Fed-Batch production phase using UF membrane to concentrate the product

Process Feature		Media Consumption		Available Manufacturing Capacity	Cell Mass		Product Residence Time
Benefit	Fed-Batch	Fed-Batch	Fed-Batch	Fed-Batch	Perfusion	Perfusion	Perfusion




1st Concept: The N-1 Perfusion Production Perfusion by Microfiltration




2nd Concept: The Hybrid Perfusion Perfusion by Microfiltration





- **Perfusion** during initial growth phase followed by fed-batch culture at very high cell concentrations
- HIPCOP: High-end pH control of perfusion
- Increased celldays result in highest titers
- Titers beyond 10 g l⁻¹ were achieved during 12 days run
- Volumetric productivities range at **1** g l⁻¹ d⁻¹ for multiple cell lines with a moderate cellular productivity


Bioreactor drawn by Dethardt Müller, modified



2018-02-14

Roland Wagner

25




Müller, modified

3rd Concept: The N-1 Perfusion Hybrid Process



Go the Extra Mile: The Concentrated Fed-Batch Concept **O** Rentschler Perfusion by Ultrafiltration


- Ultrafiltration using the XCell[™] ATF module consisting of a 30-50 kDa membrane
- Retains cells and proteins
- Concentrates proteins beyond 20 g I⁻¹ (XD[®] Process, DSM)
- Permeate allows waste removel
- Total cumulative protein content in XCell[™] ATF perfusion is ~6 times higher than in the fed-batch culture



The Concentrated Fed-Batch Concept




Process	Cell concentration [ml ⁻¹]	Titer [g l ⁻¹]	Volumetric productivity [mg l ⁻¹ d ⁻¹]	Reference
Fed-Batch	5 × 10 ⁷	8	430	Yang WC <i>et al.</i> 2016. J Biotechnol 217:1-11
Concentrated Fed-Batch	18 × 10 ⁷	25	790	Yang WC <i>et al.</i> 2016. J Biotechnol 217:1-11
XD [®] Process	15 × 10 ⁷	27	1800	Douwenga R. 2013. Bioproc Intl. Industry Yearbook: 99
Concentrated Fed-Batch	9 × 10 ⁷	37	2500	Xu S <i>et al.</i> 2017. Biotechnol Prog 33: 867-878



Impact of Continuously Perfused High Density Cultures Iso-Volumetric Productivity Lines in Efficiency / Intensity Space





Xu S et al. 2017. Biotechnol Prog 33: 867-878

Supply of an Antibody Market -Economy Determines the Process



- Case study to supply a large market (e.g. Alzheimer a worse case)
 - Potential patients: >10 million next 30 years.
 - 50 % market penetration: 5 million patients
 - Yearly demand per patient: 24 g
 - o 5 million patients: 120 000 kg
 - o 2500 kg with 20 000-I bioreactor per year
 - \circ 10 50x 20-k bioreactors required

Not a problem even with todays technology

One Step Further




Cricetulus griseus



† 1957 2n = 22 Chromosomes CHO cell size: $15 \times 15 \ \mu m$ Max. cell concentration $8 \times 10^8 \ ml^{-1}$ Doubling time: 20 h Culture temperature: 37 °C


Leishmania tarentolae



Will be born 2n = 36 Chromosomes Cell size: $15 \times 5 \mu m$ Max. cell concentration: $5 \times 10^9 ml^{-1}$ Doubling time: 6 h Culture temperature: 26 °C

Leishmaniasis Hosts





Man *Homo* sapiens Kala Azar from *Leishmania* donovani

Phlabatamus


Phlebotomus Carries promastigotes. Poikilothermic insects have an average temperature of 26 °C.




White-Spotted Wall Gecko *Tarentula annularis* Leihmaniasis from *Leishmania tarentulae*

Comparison of N-Glycan Patterns







Leishmania

- Complex type N-glycans with α-linked galactose and fucose residues.
- Very homogeneous.
- Only biantennary asialo N-glycans.
- In vitro sialylation possible.



Next Challenges Just Around the Corner

- Artificial Cells
 - Cell specific productivity
 - Stable cell lines for continuous processing
- Process Intensification
 - Highly concentrated media and feeds
 - Harvest process

- Drug Safety and Potency
 - Quality control
 - o ADC
- Processes for Gene & Cell Therapeutics
 - Viral vectors
 - o Cells as products

